(AOF) – Nanobiotix presents at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting new data highlighting the potential of NBTXR3, a first-in-class radioenhancer, in combination with concurrent chemotherapy in the treatment of head and neck cancer and rectal cancer.
Nanobiotix also presents a “poster” outlining the plan for the ongoing pivotal Phase III study, NANORAY-312, evaluating radiotherapy-activated NBTXR3 in the treatment of frail elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) not eligible for platinum-based chemotherapy.
LEXICON
Clinical trials (Phases I, II, III)
Phase I: small-scale testing of the molecule on humans to assess its safety, tolerance, metabolic and pharmacological properties. Phase II: evaluation of tolerance and efficacy on several hundred patients to identify side effects. Phase III: assessment of the overall benefit/risk ratio with several thousand patients.
AOF – LEARN MORE
Oncology supports laboratory performance
Oncology generated $163 billion in revenue in 2021 (out of an industry total of $613 billion), up 11.9%, according to GlobalData. Its average annual growth has reached 15.4% over the past twenty years. This segment, which is increasingly competitive, is dominated by a few heavyweights such as MSD (Merck & Co. Inc), Roche, BMS
.
L
‘
immuno-oncology, the specialty that has been driving this market for ten years, supports research. GlobalData estimates that this segment could reach 180 billion in 2026. The major players are looking to strengthen themselves in this niche. Pfizer recently acquired Canadian biotech Trillium Therapeutics for $2.3 billion. Following this operation, the American group got hold of two promising molecules in the treatment of blood cancer.